Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in the EU / 2026-527647-18-00
Authorised, not yet recruiting Phase IV

An exploratory double-blind randomized placebo-controlled trial to evaluate the effect of ARTENSIUM® cream in the relief of pain in patients with knee osteoarthritis

2026-527647-18-00 · tracked via the Priya Life Science EU tracker
Sponsor
Boiron
Sponsor type
Pharmaceutical company
Therapeutic area
Musculoskeletal Diseases
Decision date
06/10/2026
Enrollment target
200
Sites
France

Condition studied

Knee osteoarthritis is a chronic degenerative joint disease characterised by progressive deterioration of the articular cartilage and structural changes affecting the entire joint. Patients commonly experience knee pain, stiffness, reduced physical function and impaired quality of life. This study focuses on adults with symptomatic knee osteoarthritis experiencing knee pain requiring therapeutic management.

Investigational medicinal product(s)

Placebo cream (identical in appearance to ARTENSIUM® creamwithout active substances)ARTENSIUMcrème

Eligibility

Age group
18-64 years, 65+ years
Sex
Female, Male

Primary endpoint

Change in the KOOS Pain subscale score, assessed longitudinally between Day 0, Day 7, and Day 14, with the primary estimate of treatment effect at Day 14. If the patient experiences pain in both knees, only the most painful knee will be assessed.

Endpoint detail

Change in pain VAS score between Day 0, Day 7 and Day 14., Change in the KOOS Symptoms subscale between Day 0, Day 7 and Day 14., Change in the KOOS ADL Function subscale between Day 0, Day 7 and Day 14., Change in the KOOS Quality of Life subscale between Day 0, Day 7 and Day 14., PGIC (Patient Global Impression of Change) score at Day 0, Day 7 and Day 14., Change in pain VAS score assessed at three time points: before application, 2 hours post-application, and 4 hours post-application at the first application, and subsequently at Day 7 and Day 14 (after the morning application)., • Cumulative quantity of rescue medication used between Day 0 and Day 14 • Maximum daily quantity used between Day 0 and Day 14 • Number of daily intakes between Day 0 and Day 14., Proportion of patients requiring analgesic treatment during follow-up • Number of days with analgesic use during follow-up • Type of analgesic treatments used (paracetamol, NSAIDs, opioids, others) • Cumulative quantity of analgesics used during follow-up., Proportion of administered doses as reported in the patient diary between Day 0 and Day 14., Overall satisfaction • Ease of spreading • Texture (stickiness, residual film) • Ease of use • Odor • Visual appearance • Intention to reuse the product.

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2026-527647-18-00 on CTIS ↗ ← All trials in the EU